Mol Cell Biol, April 1998, p. 1903-1910, Vol. 18, No. 4
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Howard Hughes Medical Institute and Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544
Received 1 October 1997/Returned for modification 5 December 1997/Accepted 16 January 1998
| |
ABSTRACT |
|---|
|
|
|---|
H19 and Igf2 are reciprocally imprinted genes that lie 90 kb apart on mouse chromosome 7. The two genes are coexpressed during development, with the H19 gene expressed exclusively from the maternal chromosome and Igf2 from the paternal chromosome. It has been proposed that their reciprocal imprinting is governed by a competition between the genes for a common set of enhancers. The competition on the paternal chromosome is influenced by extensive allele-specific methylation of the H19 gene and its 5' flank, which acts to inhibit H19 transcription and thus indirectly leads to the activation of the Igf2 gene. In contrast, no allele-specific methylation has been detected on the maternal chromosome, and the basis for the preference for H19 transcription on that chromosome is unresolved. In this investigation, the mechanism controlling the silencing of the Igf2 gene on the maternal chromosome was explored by studying the transcriptional activity of a yeast artificial chromosome (YAC) containing Igf2 and H19 following transfer into differentiated tissue culture cells. Contrary to expectations, both H19 and Igf2 were expressed from a single integrated copy of the YAC. Furthermore, Igf2 expression appeared to be independent of the H19 locus, based on deletions of the H19 gene promoter and its enhancers. These results suggest that an active process is responsible for the transcriptional bias toward H19 on the maternal chromosome and that the hypomethylated state of this chromosome cannot be viewed as a "default" state. Moreover, the active process is not reproduced in a differentiated cell and may require passage through the female germ line.
| |
INTRODUCTION |
|---|
|
|
|---|
The distal end of mouse chromosome 7 contains a cluster of genes subject to regulation by genomic imprinting. The linkage of six imprinted genes within a region of ~1 Mb, namely, p57KIP2, Kvlqt1, Mash2, Insulin-2 (Ins2), Insulin-like growth factor 2 (Igf2), and H19 (4, 10a, 11, 17, 21, 24), suggests the potential for long-range regional control of imprinting. A connection between the imprinting of Igf2 and H19 was first raised by the observation that, during development, the two genes are identically expressed in endoderm and mesoderm with H19 expressed exclusively from the maternal chromosome and Igf2 expressed solely from the paternal chromosome. The common pattern of expression was explained when a targeted deletion of two endoderm-specific enhancers 3' of the H19 gene drastically reduced H19 endoderm expression when inherited on the maternal chromosome and reduced Igf2 expression upon paternal inheritance (33). Thus, the two genes require the same regulatory elements for expression, and their reciprocal imprinting may arise as the result of a competition between the genes for transcription (2).
The strong preference for Igf2 expression on the paternal chromosome is thought to arise from paternal chromosome-specific methylation of critical CpG residues in the 5' flank of the H19 gene. This methylation has all the properties of a gametic mark, as it is established in sperm but not in oocytes, is resistant to the global demethylation that occurs during preimplantation development, and is maintained in all somatic cells of the organism (3, 16, 55, 56). The consequence of this methylation is the silencing of transcription of the H19 gene, and so indirectly Igf2 is expressed (34).
On the maternal chromosome, no gametic mark has been identified, suggesting that perhaps the transcriptional status of the Igf2 and H19 genes is not mediated by epigenetic regulation. In that case the exclusive expression of H19 could be explained by either its closer proximity to the enhancers or the inherently greater strength of its promoter. According to this model, H19's relative advantage with respect to the enhancers leads directly to the silencing of the Igf2 gene. This idea was tested in experiments involving two different targeted germ line deletions of the H19 gene and its promoter that differed in the extent of the deletion of the 5' flank of the gene (32, 43). In both instances, the removal of the H19 gene and its promoter led to some degree of activation of the normally silent Igf2 gene on the maternal chromosome, consistent with the premise that transcription of the H19 gene precludes Igf2 expression.
We set out to determine whether we could recapitulate the transcriptional state of the maternal chromosome using a yeast artificial chromosome (YAC) that contains the two genes as well as the tightly linked Ins2 gene. YACs have proven useful in the analysis of large gene complexes in mammals, as they can be readily modified in yeast and then transferred into either tissue culture cells or mice (26, 27, 37, 46, 52). As Saccharomyces cerevisiae lacks the CpG methylation found in mammals, the YACs were expected to mimic the hypomethylated state of the maternal chromosome. Modified YACs were then transferred to Hep3B cells to determine whether the exclusive maternal expression of H19 could be established in a fully differentiated cell.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Strains and microbial techniques.
Strains used in this study
were AB1380 (MATa ura3 lys2-1oc ade2-101c trp1
his5am can1-100oc) and YPH925 (MAT
ura3-52 lys2-801
ade2-101 trp1-63 his3-200 leu2-1 cyh2R
kar1-15). The standard yeast media and genetic techniques
that were employed are described by Rose et al. (44). The
FEW.A12neo YAC was transferred from AB1380 to
YPH925 as described by Spencer et al. (50). Transformation
of YAC-containing strains utilized lithium acetate transformation
(44).
Isolation and characterization of FEW.A12. The FEW.A12 Igf2/H19 YAC was isolated from the Massachusetts Institute of Technology mouse YAC library by PCR-based screening (19, 30). High-molecular-weight DNA from YAC strains and Hep3B cell lines was prepared in agarose blocks (9). Following three 30-min washes at 25°C in 10 mM Tris-HCl-1 mM EDTA (pH 8.0) and three 15-min washes at the appropriate digestion temperature in 1× digestion buffer, plugs were digested with restriction enzymes and separated by pulsed-field gel electrophoresis (PFGE) in a 1% agarose gel with a contour-clamped homogeneous electric field (CHEF) gel apparatus at 15°C (10).
DNA analysis. The structures of the Igf2/H19 locus in FEW.A12 and the three modified versions before and after transfection into Hep3B cell lines were analyzed by restriction enzyme digestion followed by either electrophoresis in 0.8% agarose gels or PFGE. The DNAs were transferred to nitrocellulose (49) and hybridized to DNA fragments that had been labeled with [32P]dCTP by nick translation (42).
Generation of modified YACs. (i) FEW.A12neo. To construct an Igf2/H19 YAC containing the neomycin resistance gene (neoR) integrated at Ins2, a yeast integrating plasmid was constructed; it contained a 785-bp fragment from Ins2 (probe 1 [see Fig. 1]) that was generated by PCR with the forward primer 5'-TGAAGTGGAGGACCCACAAG-3' and the reverse primer 5'-GGATGCAGAGGGAACCAAAG-3'. The targeting vector also contained neoR and the yeast genetic marker LYS2. The vector was linearized at a unique SmaI site within the Ins2 sequence prior to transformation of the AB1380 strain harboring FEW.A12. LYS+ transformants were assayed by digestion of genomic DNA with HincII and analysis by Southern blotting with probe 1, the yeast LYS2 gene, or a 630-bp PstI-XbaI fragment from neoR. High-molecular-weight DNA from transformants was subjected to PFGE, Southern blotting, and hybridization with the EcoRI-SalI fragment encompassing the H19 gene (probe 8 [see Fig. 1]) to verify that the modified YAC was the same size as FEW.A12.
(ii) FEW.A12
p.
To construct an
Igf2/H19 YAC with a deletion of the H19 promoter
(FEW.A12
p), a targeting vector was constructed in pRS405
(47); the vector contained a 1.0-kb
BamHI-XbaI fragment from the 5' flank of
H19, a 680-bp DraIII-BamHI fragment
from the region immediately downstream of the H19
transcription start site, and the yeast genetic marker LEU2.
The vector was linearized at a unique BamHI site between the
two H19 flanking sequences prior to transformation of the YPH925 strain harboring the FEW.A12neo YAC.
LEU+ transformants were assayed by digesting genomic DNA
with EcoRI followed by Southern blotting. Blots were
hybridized separately with the 4-kb EcoRI fragment from the
5' flank of H19 (probe 7 [see Fig. 1]) or the 8-kb
SalI-EcoRI fragment 3' of the H19
gene. Additionally, HindIII-digested DNA was hybridized
to a 750-bp XbaI-EcoRI fragment from within the
deleted promoter region to verify that the region had been removed.
(iii) FEW.A12
e.
To construct an
Igf2/H19 YAC with a deletion of the H19 enhancers
(FEW.A12
e), a targeting vector was constructed in pRS403
(47); the vector contained a 2.6-kb
SacI-XbaI fragment from the region 5' of the H19 enhancers, a 3.7-kb BamHI-EcoRI
fragment from the region 3' of the enhancers, and the yeast markers
CYH2 and HIS3. The plasmid was linearized at a
unique NsiI site within the SacI-XbaI
fragment after destroying an NsiI site within the noncoding
region of HIS3. Genomic DNA from HIS3+
transformants was digested with BglII or XmnI
followed by Southern blotting with probe 8, the 2.4 kb
XbaI-BglII enhancer fragment (probe 9), and a
200-bp PCR product amplified from a region 3' of the DNA used in the
targeting vector (probe 11) (33). Two-step gene replacement
resulted in deletion of the H19 enhancer region.
Lipofection of Hep3B cells. The Hep3B cell line and the transfected cell lines were maintained in Dulbecco modified Eagle medium with 10% fetal calf serum. Transfected cell lines were maintained in media with 250 µg of active G418 per ml. One day prior to lipofection, 2.5 × 106 Hep3B cells were seeded onto 6-cm tissue culture plates to achieve 90 to 95% confluence on the day of lipofection. Approximately 2 h prior to lipofection, cells were washed once with OptiMEM (Gibco BRL) and incubated in 3 ml of OptiMEM. YAC lipofection into Hep3B cells was done essentially as described by Lee and Jaenisch (31). High-molecular-weight DNA from YAC strains was embedded in agarose blocks and subjected to PFGE in a 1% low-melting-point agarose gel with a single slot trough in a CHEF gel apparatus at 15°C. The appropriate gel slice was excised from the unstained portion of the gel, dialyzed in 20 mM Tris-HCl (pH 7.6)-1 mM EDTA-200 to 400 µM spermine at 25°C and used within a few days.
On the day of transfection, poly-L-lysine was added to the gel slice to a final concentration of 4 µg/ml. The tube was warmed to 65 to 68°C until the gel melted and was then equilibrated at 40°C for 5 min. Agarose was digested with 15 U of
-agarase at 40°C for
1 to 2 h. DOTAP lipid (20 µg) was added, and the DNA-lipid complex was incubated at room temperature for 30 min. The mixture was
then equilibrated in Dulbecco modified Eagle medium, and 1.5 ml of
OptiMEM was added. The monolayer of Hep3B cells was washed with
OptiMEM, and the transfection complex was applied to the monolayer with
a wide-bore pipette. After 4 h, the cells were incubated in fresh
medium with serum for 12 to 18 h. Two days later, 250 µg of
active G418 per ml was applied; resistant colonies were picked
approximately 2 to 3 weeks later.
Identification of YAC-containing cell lines. A small aliquot of cells was removed for quick DNA preparation with lysis buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl2, 0.45% Nonidet P-40, and 0.45% Tween 20. The mouse H19 and Igf2 genes were identified by PCR with, for H19, the forward primer 5'-GTACCCACCTGTCGTCC-3' and the reverse primer 5'-GTCCACGAGACCAATGACTG-3' and, for Igf2, the forward primer 5'-CTTCACTGGTCATTCCATCAC-3' and the reverse primer 5'-GCAGCAGCAGAACTAGATGATTGG-3'. Cell lines that were positive for both genes were lysed (25), and the DNA was prepared (18). To verify that the DNA surrounding the two genes was intact, DNA (15 µg) was digested separately with EcoRI and BglII and hybridized successively to probes 2 and 8. The copy number was determined by comparison to signals from the endogenous genes. Finally, high-molecular-weight DNA was digested with BssHII, EagI, or SacII followed by PFGE and hybridization to probes 2 and 8. Cell lines in which the YAC H19 and Igf2 genes mapped to the same high-molecular-weight DNA fragment were chosen for subsequent expression analysis.
DNA methylation analysis. Genomic DNA (15 µg) was digested overnight with SacI (H19) or EcoRI plus HindIII (Igf2 differentially methylated region [DMR] 1) in combination with HpaII or MspI and hybridized to probe 7 (for H19) and a 717-bp EcoRI-XbaI probe from the 5' upstream region of Igf2 (DMR 1) (6).
RNA isolation and analysis. Total RNA was isolated by guanidinium hydrochloride extraction (1). Single-stranded RNase protection probes were synthesized by in vitro transcription in the presence of [32P]CTP and purified by gel electrophoresis. RNase protection was performed with a non-allele-specific H19 probe (8) or a 400-bp XbaI-BamHI fragment derived from the 3' untranslated region of Igf2 according to the directions in the Ribonuclease Protection Assay kit (Ambion). For Northern analysis, RNA (10 µg) was electrophoresed in 1.5% agarose gels in 0.02 M 3-[N-morpholino]propanesulfonic acid-5 mM sodium acetate-1 mM EDTA. RNA was transferred to nitrocellulose (54) and hybridized to a 1.4-kb PstI-EcoRI probe from the 3' end of the human H19 cDNA or probe 2.
| |
RESULTS |
|---|
|
|
|---|
Isolation and characterization of a large Igf2/H19 YAC. In order to study long-range regulation of transcription in the Igf2/H19 gene cluster, a 630-kb YAC (FEW.A12) containing both genes was isolated from the Massachusetts Institute of Technology mouse YAC library by PCR. To confirm that the YAC was a faithful representation of the ~130 kb of the mouse genome that contains the Ins2, Igf2, and H19 genes, DNA from the yeast strain harboring the YAC was digested with both rare-cutting and frequent-cutting restriction enzymes followed by hybridization to probes within the Igf2/H19 locus (Fig. 1). The probes were derived from the Ins2, Igf2, and H19 genes as well as the 75-kb intergenic region (probes 3, 4, 5, and 6) and DNA 3' of H19 (probe 10). These analyses revealed that the genes were situated roughly in the middle of the YAC on ~125-kb EagI and SacII restriction fragments. Furthermore, no differences in the structure of the region were detected in a comparison with mouse genomic DNA (data not shown).
|
Expression of the Igf2/H19 YAC in Hep3B cells. In order to transfer the Igf2/H19 YAC into tissue culture cells, a neomycin resistance (neoR) selectable marker was introduced into the Ins2 gene located 15 kb upstream of Igf2 by using a yeast integration plasmid (Fig. 2A). The modified YAC, termed FEW.A12neo, was transferred by lipofection into Hep3B cells, a human hepatoma cell line that expresses both the Igf2 and H19 genes at high levels. Colonies containing the YAC DNA were selected in the presence of G418 and screened for Igf2 and H19 by PCR, followed by restriction mapping by Southern blotting to verify that the genes had been transferred intact (Table 1).
|
|
|
|
Effect of deletion of the H19 promoter on expression of Igf2. Although H19 and Igf2 were both expressed from the transfected YAC, it is possible that promoter competition was occurring, albeit with a relaxation in the strong preference for H19 transcription. If this were true, however, the level of Igf2 expression would be expected to increase upon mutation at the H19 locus. Alternatively, there might be no mechanistic link between the expression of the two genes on the YAC, in which case mutations at H19 would have no impact on Igf2. To discriminate between these alternatives, we modified the YAC by deleting an 800-bp XbaI-DraIII fragment spanning the 5' flank and promoter of H19. In its place, the yeast LEU2 gene was integrated (Fig. 2B).
In order to accomplish this modification, it was necessary to move the FEW.A12neo YAC to another yeast host that harbored additional auxotrophic mutations like leu2 and his3. The kar1 mutant strain YPH925 is defective in normal karyogamy; therefore, matings between the kar1 mutant strain and the YAC-containing KAR1+ AB1380 strain result in "cytoductants," daughter cells with one haploid parental genotype but a mixed parental cytoplasm. A minority (0.1%) of cytoductants are rare "chromoductants" that have gained chromosomal information from the other parent. By using a mating scheme that selects for transfer of the YAC as well as maintenance of the recipient haploid YPH925 genome, we selected for "YACductants" that had transferred the FEW.A12neo YAC to YPH925 (50). Once established, the new strain was transfected with the integration plasmid and the proper integrants were selected and confirmed by Southern blotting. The modified YAC, called FEW.A12
p, was transferred to
Hep3B cells, and 15 neoR colonies that were
positive for both Igf2 and H19 by PCR were identified. Three lines, all containing a single copy of the YAC, were
shown by both conventional electrophoresis and PFGE and hybridization to contain the two intact genes linked on the same large restriction fragment (Table 1 and data not shown).
RNase protection assays were used to assess expression of the imprinted
genes in FEW.A12
p cell lines. As expected,
H19 expression was nearly undetectable in the absence of the
H19 promoter (Fig. 4). Northern analysis revealed that the
very faint signal observed in RNase protection was derived from a
larger-sized transcript that was most likely initiated at a cryptic
promoter(s) within the plasmid sequences upstream of the H19
structural gene (data not shown). Despite the loss of the
H19 promoter, Igf2 RNA was expressed in these lines at levels comparable to those obtained with the
FEW.A12neo YAC (Fig. 4). Thus, in contrast to
previous findings that had demonstrated that the loss of the
H19 gene and its promoter increased the level of expression
of Igf2 in vivo (32), expression of Igf2 in the YAC-containing cell lines was independent of the
H19 promoter.
Independence of Igf2 expression on the H19
enhancers.
The lack of dependence of Igf2 transcription
on the status of H19 transcription in Hep3B cells could be
explained if the Igf2 gene did not require the
H19 enhancers for its expression. Leighton et al.
(33) have shown that, in vivo, endodermal expression of the
Igf2 gene from the paternal chromosome is absolutely
dependent upon two enhancers in the 3' flank of the H19
gene. To delete the H19 enhancers from the YAC, we
constructed a yeast integration plasmid containing the yeast markers
CYH2 and HIS3. Two-step gene replacement resulted
in a YAC, designated FEW.A12
e, bearing a 6.2-kb deletion
that encompassed the H19 endoderm enhancers and was
identical to the germ line deletion constructed by Leighton et al.
(33) (Fig. 2C).
e lines but was absent from a multicopy
line, FEW.A12
e.X3. Furthermore, all four lines expressed
Igf2, although at slightly different levels (Fig. 4).
Interestingly, the Igf2 gene was expressed in the
FEW.A12
e.X3 line, where H19 expression was
repressed. These data suggest that Igf2 expression is
independent of sequences at the H19 locus within the context
of the transfected YAC.
Methylation of H19 and Igf2. One confounding factor in these experiments that could account for the difference between the behavior of the genes in Hep3B cells and in their normal context could be inappropriate DNA methylation of the YAC. On the maternal chromosome in vivo, no allele-specific methylation has been detected at Igf2 or H19 although there is extensive DNA methylation on both chromosomes in the region between the two genes (29). At the point of gene transfer, the YACs were completely unmethylated; however, it is possible that they acquired methylation once they were integrated into Hep3B cells.
To determine whether this was the case, we investigated the methylation status of the H19 gene in cell lines containing FEW.A12neo. The CpG sites that are thought to constitute the gametic imprint in the 5' flank of the H19 gene are contained within a 3.7-kb SacI fragment immediately upstream of the promoter. We examined the methylation of this fragment by digestion with SacI alone or in combination with the methylation-sensitive enzyme HpaII or its methylation-insensitive isoschizomer, MspI. The 3.7-kb SacI fragment was completely digested by HpaII in the three cell lines containing FEW.A12neo (E6, G3, and I1 [Fig. 5A]), indicating that the region of the gametic imprint was unmethylated on the YAC, as it is on the maternal chromosome. Likewise, the SacI fragment, which is present in its entirety in FEW.A12
p, was
completely digested in the three FEW.A12
p lines (K7, L8,
and O7 [Fig. 5A]), demonstrating that the lack of H19
transcription does not lead to DNA methylation.
|
p cell lines displayed
no fully resistant, methylated fragments (E6, G3, I1, K7, L8, and O7
[Fig. 5B]), indicating that although expression of Igf2 in
these lines was comparable to the levels in neonatal liver, DNA
methylation was not required in this context for expression.
| |
DISCUSSION |
|---|
|
|
|---|
The maternal chromosome encoding the Igf2/H19 gene cluster has been viewed as the "default" chromosome, that is, the chromosome without allele-specific epigenetic modifications such as DNA methylation. As such, we would predict that when an unmethylated YAC containing the Igf2 and H19 genes was introduced into tissue culture cells competent to express both genes, H19 would be expressed to the exclusion of Igf2, as observed in vivo. Contrary to expectations, the YAC-containing cell lines expressed both genes at levels comparable to or even higher than those observed in neonatal liver. Furthermore, no evidence for transcriptional interaction between the genes could be demonstrated from the modified YACs in which the H19 promoter or its enhancers had been deleted. These results suggest that DNA introduced into a differentiated cell is missing an epigenetic modification that is required to silence the Igf2 gene on the maternal chromosome.
One caveat to this conclusion is that the neoR marker was inserted just 15 kb away from the Igf2 gene. The insertion of neoR into the tightly linked Ins2 gene was intended to maximize the likelihood that neoR lines would contain the genes of interest. It is possible, however, that by imposing a requirement for neoR gene expression, we selected for integration sites that were also conducive to Igf2 expression. On the other hand, Sasaki et al. (45) have shown that the maternal Igf2 promoter is in an open, hypersensitive state, yet its transcription is repressed. Therefore, although the presence of the neoR marker may have selected for open chromatin in the Igf2 region, the situation is not unlike that found in vivo.
Another possible explanation for the coexpression of Igf2 and H19 from the YAC is the requirement for species-specific trans-acting factors for imprinting. To date, the acquisition of an imprinted state of a human gene in a mouse cell, or vice versa, has not been demonstrated. In this regard, it is intriguing that the sequences of the candidate gametic mark regions of both H19 and Igf2r are not conserved in primary sequence between mouse and human cells, although each is subject to allele-specific methylation (28, 48, 55, 56). Furthermore, although Hep3B cells express both genes, it is unknown whether the genes are imprinted. This would be difficult, if not impossible, to determine, because the cells are no longer diploid.
It is formally possible that coexpression of the genes on the integrated YAC DNA reflects an absence of cis-acting sequences rather than trans-acting factors. That is, the YAC DNA could be missing sequences required to establish the Igf2 imprint. We view this as unlikely based on findings that 14-kb H19 transgenes are imprinted in heterologous chromosomal locations (3, 13, 38), and the deletion of a subset of those sequences in the germ line prevents Igf2 imprinting (32).
The explanation we favor is that some germ line modification is required to set up the silencing of Igf2; therefore the maternal chromosome is not a true "default" state. Since the YAC DNA was transfected into a differentiated cell line, epigenetic modifications that are acquired during either passage through the germ line or differentiation would be missing. Support for a requirement for germ line passage comes from the work of Tucker et al. (57). Those authors showed that in DNA methyltransferase (Dnmt)-deficient ES cells, which had lost almost all genome methylation, reintroduction of Dnmt cDNA restored proper methylation and expression of nonimprinted genes but failed to do so for imprinted genes. Only after germ line transmission of these ES cells were the proper methylation and expression patterns of the imprinted genes H19, Igf2, and Igf2r restored (57). In that study, however, the lack of DNA methylation resulted in bi-allelic H19 expression and silencing of Igf2, not the coexpression we observed. Therefore, one must conclude that the epigenetic modification that is missing in the YAC experiments may not be DNA methylation itself but possibly a chromatin conformation that cannot be assembled in a differentiated cell.
A similar requirement for germ line transmission in order to establish
appropriate expression is provided by the human
-globin cluster,
where developmental switching is thought to proceed via a competition
between genes. In this example, genes compete for the locus control
region, a large chromatin region consisting of multiple DNase I
hypersensitive sites that sequentially engages the embryonic, fetal,
and adult genes (12, 20). When YACs containing the region
are transferred through the mouse germ line, the appropriate temporal
regulation of the gene cluster is recapitulated (5, 14, 23).
Transfer of a globin YAC into mouse erythroleukemia cells, however,
resulted in coexpression of fetal and adult globin genes shortly after
transfer of the YAC despite the adult environment of the mouse
erythroleukemia cells (37). Ten to 20 weeks in culture were
required for exclusive adult
-globin expression to occur.
It is striking that for the modified YACs, Igf2 expression
appears to be independent of sequences at the H19 locus.
That is, the overall activity of the Igf2 promoter was
unaffected by a deletion of the H19 promoter, arguing
strongly that the genes are not competing in this context for access to
transcriptional elements. Even more surprising, neither gene showed any
dependence upon the H19 enhancers for high-level expression.
By both transient transfection into Hep3B cells and stable expression
in transgenic mice, the H19 gene has been shown to be
dependent upon the 3' enhancers (13, 60). That dependence
was also demonstrated at the endogenous locus, by showing that mice
with a germ line deletion of the enhancers had reduced levels of
expression of both H19 and Igf2 (33).
Thus, the behavior of the transfected FEW.A12
e YAC is
difficult to understand. One resolution would be the utilization of
enhancers for which the genes do not compete.
A possible precedent for this comes from the observation that there is coexpression of H19 and Igf2 on the maternal chromosome in the choroid plexus and leptomeninges, two tissues in the brain in which the imprinting of Igf2 is absent but the imprinting of H19 is maintained (11, 53). Although the basis for this has not been determined, it is possible that it reflects the action of enhancers for which the genes do not compete. In fact, mice carrying a deletion of the 3' H19 endoderm enhancers maintain choroid plexus expression of both genes, arguing for a separate, yet-to-be-identified enhancer(s) for that tissue (33). It is conceivable that these enhancers are contained on the integrated YAC DNA and inappropriately activated, thereby explaining both the coexpression and the lack of dependence on the H19 enhancers.
In a recent study we observed coexpression of the two genes in mice by supplying the maternal chromosome with a second set of enhancers approximately equidistant from the two genes. In that instance, the requirement for competition was eliminated by the duplication of the enhancers (59). Furthermore, in pathological conditions such as Beckwith Wiedemann syndrome and in transformed cells, it has been shown that there is relaxation of Igf2 imprinting (22, 36, 39, 41). In some instances this is accompanied by a loss of expression of maternal H19, a finding that is readily explained by the competition model (35, 40, 51). In other instances, however, it appears that the two genes are coexpressed on the maternal chromosome (7), much as we have observed in these studies. Although it has been assumed that the relaxation is cis mediated, it is conceivable that it is due to the loss of a trans-acting factor during transformation that is required for gene silencing. If the latter is the case, the coexpression of the transfected genes in transformed Hep3B cells would be explained.
In conclusion, we have shown that expression of the H19 and Igf2 genes appears to be unlinked in an in vitro system whereby modified YACs are transfected into differentiated tissue culture cells. The YACs remained hypomethylated at the Igf2 and H19 loci, however, suggesting that they are mimicking the maternal chromosome, at least in terms of hypomethylation. These data suggest that the hypomethylated maternal chromosome might not be a default state and that an active process during either germ line passage or differentiation is required in vivo to achieve the silencing of the Igf2 gene.
| |
ACKNOWLEDGMENTS |
|---|
We thank the members of the Rose, Broach, and Waters labs for advice and reagents; William Strauss for advice on YAC lipofection; and members of the Tilghman lab, especially Laurie Jo Kurihara and Lisa Sandell, for continued interest and support. We thank Sharon Zemel, who identified the Igf2/H19 YAC.
This work was supported by a grant from the National Institute of General Medical Sciences. S.M.T. is an Investigator of the Howard Hughes Medical Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: HHMI, Department of Molecular Biology, Princeton University, Princeton, NJ 08544. Phone: (609) 258-2900. Fax: (609) 258-3345. E-mail: stilghman{at}molbio.princeton.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1988. . Current protocols in molecular biology, vol. 1. John Wiley & Sons, New York, N.Y. |
| 2. | Bartolomei, M. S., and S. M. Tilghman. 1992. Parental imprinting of mouse chromosome 7. Semin. Dev. Biol. 3:107-117. |
| 3. |
Bartolomei, M. S.,
A. L. Webber,
M. E. Brunkow, and S. M. Tilghman.
1993.
Epigenetic mechanisms underlying the imprinting of the mouse H19 gene.
Genes Dev.
7:1663-1673 |
| 4. | Bartolomei, M. S., S. Zemel, and S. M. Tilghman. 1991. Parental imprinting of the mouse H19 gene. Nature 351:153-155[Medline]. |
| 5. |
Behringer, R. R.,
T. M. Ryan,
R. D. Palmiter,
R. L. Brinster, and T. M. Townes.
1990.
Human - to -globin gene switching in transgenic mice.
Genes Dev.
4:380-389 |
| 6. | Brandeis, M., T. Kafri, M. Ariel, J. R. Chaillet, J. McCarrey, A. Razin, and H. Cedar. 1993. The ontogeny of allele-specific methylation associated with imprinted genes in the mouse. EMBO J. 12:3669-3677[Medline]. |
| 7. |
Brown, K. W.,
A. J. Villar,
W. Bickmore,
J. Clayton-Smith,
D. Catchpole,
E. R. Maher, and W. Reik.
1996.
Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway.
Hum. Mol. Genet.
5:2027-2032 |
| 8. |
Brunkow, M. E., and S. M. Tilghman.
1991.
Ectopic expression of the H19 gene in mice causes prenatal lethality.
Genes Dev.
5:1092-1101 |
| 9. |
Carle, G. F., and M. V. Olson.
1985.
An electrophoretic karyotype for yeast.
Proc. Natl. Acad. Sci. USA
82:3756-3760 |
| 10. |
Chu, G.,
D. Vollrath, and R. W. Davis.
1986.
Separation of large DNA molecules by contour-clamped homogenous electric fields.
Science
234:1582-1585 |
| 10a. | Cleary, M. A., and S. M. Tilghman. Unpublished results. |
| 11. | DeChiara, T. M., E. J. Robertson, and A. Efstratiadis. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64:849-859[Medline]. |
| 12. | Dillon, N., and F. Grosveld. 1993. Transcriptional regulation of multigene loci: multilevel control. Trends Genet. 9:134-137[Medline]. |
| 13. | Elson, D. A., and M. S. Bartolomei. 1997. A 5' differentially methylated sequence and the 3' flanking region are necessary for H19 transgene imprinting. Mol. Cell. Biol. 17:309-317[Abstract]. |
| 14. | Enver, T., N. Raich, A. J. Ebens, T. Papayannopoulou, F. Costantini, and G. Stamatoyannopoulos. 1990. Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. Nature 344:309-313[Medline]. |
| 15. | Feil, R., J. Walter, N. D. Allen, and W. Reik. 1994. Developmental control of allelic methylation in the imprinted mouse Igf2 and H19 genes. Development 120:2933-2943[Abstract]. |
| 16. | Ferguson-Smith, A. C., H. Sasaki, B. M. Cattanach, and M. A. Surani. 1993. Parental-origin-specific epigenetic modifications of the mouse H19 gene. Nature 362:751-755[Medline]. |
| 17. | Giddings, S. J., C. D. King, K. W. Harman, J. F. Flood, and L. R. Carnaghi. 1994. Allele specific inactivation of insulin 1 and 2, in the mouse yolk sac, indicates imprinting. Nat. Genet. 6:310-313[Medline]. |
| 18. |
Godbout, R.,
R. Ingram, and S. M. Tilghman.
1986.
Multiple regulatory elements in the intergenic region between the -fetoprotein and albumin genes.
Mol. Cell. Biol.
6:477-487 |
| 19. |
Green, E. D., and M. V. Olson.
1990.
Systematic screening of yeast artificial-chromosome libraries by use of the polymerase chain reaction.
Proc. Natl. Acad. Sci. USA
87:1213-1217 |
| 20. |
Grosveld, F.,
G. Blom van Assendelft,
D. R. Greaves, and G. Kollias.
1987.
Position-independent, high-level expression of the human -globin gene in transgenic mice.
Cell
51:975-985[Medline].
|
| 21. | Guillemot, F., T. Caspary, S. M. Tilghman, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, D. J. Anderson, A. L. Joyner, J. Rossant, and A. Nagy. 1995. Genomic imprinting of Mash-2, a mouse gene required for trophoblast development. Nat. Genet. 9:235-241[Medline]. |
| 22. | Hall, J. G. 1997. Genomic imprinting: nature and clinical relevance. Annu. Rev. Med. 48:35-44[Medline]. |
| 23. |
Hanscombe, O.,
D. Whyatt,
P. Fraser,
N. Yannoutsos,
D. Greaves,
N. Dillon, and F. Grosveld.
1991.
Importance of globin gene order for correct developmental expression.
Genes Dev.
5:1387-1394 |
| 24. | Hatada, I., and T. Mukai. 1995. Genomic imprinting of p57/KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat. Genet. 11:204-206[Medline]. |
| 25. | Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cultures. J. Mol. Biol. 26:365-369[Medline]. |
| 26. | Huxley, C., Y. Hagino, D. Schlessinger, and M. V. Olson. 1991. The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion. Genomics 9:742-750[Medline]. |
| 27. | Jakobovits, A., A. L. Moore, L. L. Green, G. J. Vergara, C. E. Maynard-Currie, H. A. Austin, and S. Klapholz. 1993. Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature 362:255-258[Medline]. |
| 28. |
Jinno, Y.,
K. Sengoku,
M. Nakao,
K. Tamate,
T. Mitamoto,
T. Matsuzaka,
J. S. Sutcliffe,
T. Anan,
N. Takuma,
K. Nishiwaki,
Y. Ikeda,
T. Ishimaru,
M. Ishikawa, and N. Niikawa.
1996.
Mouse/human sequence divergence in a region with a paternal-specific methylation imprint at the human H19 locus.
Hum. Mol. Genet.
5:1155-1161 |
| 29. | Koide, T., J. Ainscough, M. Wugerde, and M. A. Surani. 1994. Comparative analysis of Igf-2/H19 imprinted domain: identification of a highly conserved intergenic DNase I hypersensitive region. Genomics 24:1-8[Medline]. |
| 30. | Kusumi, K., J. S. Smith, J. A. Segre, D. S. Koos, and E. S. Lander. 1993. Construction of a large insert yeast artificial chromosome library of the mouse genome. Mamm. Genome 4:391-392[Medline]. |
| 31. |
Lee, J. T., and R. Jaenisch.
1996.
A method for high efficiency YAC lipofection into murine embryonic stem cells.
Nucleic Acids Res.
24:5054-5055 |
| 32. | Leighton, P. A., R. S. Ingram, J. Eggenschwiler, A. Efstratiadis, and S. M. Tilghman. 1995. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375:34-39[Medline]. |
| 33. |
Leighton, P. A.,
J. R. Saam,
R. S. Ingram,
C. L. Stewart, and S. M. Tilghman.
1995.
An enhancer deletion affects both H19 and Igf2 expression.
Genes Dev.
9:2079-2089 |
| 34. | Li, E., C. Beard, and R. Jaenisch. 1993. The role of DNA methylation in genomic imprinting. Nature 366:362-365[Medline]. |
| 35. | Moulton, T., T. Crenshaw, Y. Hao, J. Moosikasuwan, N. Lin, F. Dembitzer, T. Hensle, L. Weiss, L. McMorrow, T. Loew, W. Kraus, W. Gerald, and B. Tycko. 1994. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet. 7:440-447[Medline]. |
| 36. | Ogawa, O., M. R. Eccles, J. Szeto, L. A. McNoe, K. Yun, M. A. Maw, P. J. Smith, and A. E. Reeve. 1993. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362:749-751[Medline]. |
| 37. |
Peterson, K. R.,
G. Zitnik,
C. Huxley,
C. H. Lowrey,
A. Gnirke,
K. A. Leppig,
T. Papayannopoulou, and G. Stamatoyannopoulous.
1993.
Use of yeast artificial chromosomes (YACs) for studying control of gene expression: correct regulation of the genes of a human -globin locus YAC following transfer to mouse erythroleukemia cell lines.
Proc. Natl. Acad. Sci. USA
90:11207-11211 |
| 38. |
Pfeifer, K.,
P. A. Leighton, and S. M. Tilghman.
1996.
The structural H19 gene is required for its own imprinting.
Proc. Natl. Acad. Sci. USA
93:13876-13883 |
| 39. | Rainier, S., L. A. Johnson, C. J. Dobry, A. J. Ping, P. E. Grundy, and A. P. Feinberg. 1993. Relaxation of imprinted genes in human cancer. Nature 362:747-750[Medline]. |
| 40. |
Reik, W.,
K. W. Brown,
H. Schneid,
Y. LeBouc,
W. Bickmore, and E. R. Maher.
1995.
Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by an altered imprinting pattern in the IGF2-H19 domain.
Hum. Mol. Genet.
4:2379-2385 |
| 41. | Reik, W., and E. R. Maher. 1997. Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. Trends Genet. 13:330-334[Medline]. |
| 42. | Rigby, P. W. J., M. Dieckmann, D. Rhodes, and P. Berg. 1977. Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J. Mol. Biol. 113:237-251[Medline]. |
| 43. |
Ripoche, M.-A.,
C. Kress,
F. Poirier, and L. Dandolo.
1997.
Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element.
Genes Dev.
11:1596-1604 |
| 44. | Rose, M. D., F. Winston, and P. Hieter. 1990. . Methods in yeast genetics: a laboratory course manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 45. |
Sasaki, H.,
P. A. Jones,
J. R. Chaillet,
A. C. Ferguson-Smith,
S. Barton,
W. Reik, and M. A. Surani.
1992.
Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor (Igf2) gene.
Genes Dev.
6:1843-1856 |
| 46. | Schedl, A., L. Montoliu, G. Kelsey, and G. Schutz. 1993. A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice. Nature 362:258-261[Medline]. |
| 47. | Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:9-27. |
| 48. |
Smrzka, O. W.,
I. Fae,
R. Stoger,
R. Kurzbauer,
G. F. Fischer,
T. Henn,
A. Weith, and D. P. Barlow.
1995.
Conservation of a maternal-specific methylation signal at the human IGF2R locus.
Hum. Mol. Genet.
4:1945-1952 |
| 49. | Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517[Medline]. |
| 50. | Spencer, F., Y. Hugerat, G. Simchen, O. Hurko, C. Connelly, and P. Hieter. 1994. Yeast kar1 mutants provide an effective method for YAC transfer to new hosts. Genomics 22:118-126[Medline]. |
| 51. | Steenman, M. J. C., S. Rainier, C. J. Dobry, P. Grundy, I. L. Horon, and A. P. Feinberg. 1994. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7:433-439[Medline]. |
| 52. |
Strauss, W. M.,
J. Dausman,
C. Beard,
C. Johnson,
J. B. Lawrence, and R. Jaenisch.
1993.
Germline transmission of a yeast artificial chromosome spanning the murine 1 (I) collagen locus.
Science
259:1904-1907 |
| 53. | Svensson, K., C. Walsh, R. Fundele, and R. Ohlsson. 1995. H19 is imprinted in the choroid plexus and leptomeninges of the mouse foetus. Mech. Dev. 51:31-37[Medline]. |
| 54. |
Thomas, P. S.
1980.
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Proc. Natl. Acad. Sci. USA
77:5201-5205 |
| 55. | Tremblay, K. D., K. L. Duran, and M. S. Bartolomei. 1997. A 5' 2-kilobase-pair region of the imprinted mouse H19 gene exhibits exclusive paternal methylation throughout development. Mol. Cell. Biol. 17:4322-4329[Abstract]. |
| 56. | Tremblay, K. D., J. R. Saam, R. S. Ingram, S. M. Tilghman, and M. S. Bartolomei. 1995. A paternal-specific methylation imprint marks the alleles of the mouse H19 gene. Nat. Genet. 9:407-413[Medline]. |
| 57. |
Tucker, K. L.,
C. Beard,
J. Dausman,
J. Jackson-Grusby,
P. W. Laird,
H. Lei,
E. Li, and R. Jaenisch.
1996.
Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes.
Genes Dev.
10:1008-1020 |
| 58. | Walter, J., N. Allen, T. Kruger, S. Engemann, G. Kelsey, R. Feil, T. Forne, and W. Reik. 1996. Genomic imprinting and modifier genes in the mouse, p. 195-213. In V. E. A. Russo, R. A. Martienssen, and A. D. Riggs (ed.), Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 59. | Webber, A. L., R. S. Ingram, J. M. Levorse, and S. M. Tilghman. 1998. . Location of enhancers is essential for imprinting of H19 and Igf2. Nature, in press. |
| 60. |
Yoo-Warren, H.,
V. Pachnis,
R. S. Ingram, and S. M. Tilghman.
1988.
Two regulatory domains flank the mouse H19 gene.
Mol. Cell. Biol.
8:4707-4715 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|